Entheon Biomedical

CNSX:ENBI ISIN:CA29383X1116

Entheon BiomedicalEntheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective N,N-dimethyltryptamine based psychedelic therapeutic products ("DMT Products") for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.

     

News

Ellis Martin Report: Entheon Biomedical's (CNSX:ENBI) HaluGen Psychedelics Genetic Test Ahead of Ethical Clinical DMT Therapy

🕔3/10/2021 2:14:41 PM 2786

Join Ellis Martin for a conversation with Timothy Ko, the CEO of Entheon Biomedical (CNSX:ENBI) (OTCMKTS:ENTBF). Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of the DMT molecule.

Read Full Article

Ellis Martin Report: Entheon Biomedical (CNSX:ENBI) CEO Timothy Ko on the Ethical Clinical Use of DMT for Treating Substance Abuse, Depression, Anxiety and More

🕔2/16/2021 10:22:56 AM 3358

Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of the DMT molecule. Entheon exists to invert the addiction-recovery ratio, turning the 'untreatable case' and 'lost cause' from the norm to the exception.

Read Full Article
###

1,035 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 28) (Last 30 Days: 194) (Since Published: 1035) 

Company Data

    Principal Sector
  • Drugs & OTC 
  • Principal Industry
  • Pharmaceutical 
  • Homepage
  • www.entheonbiomedical.com
  • E:
  • Joe@entheonbiomedical.com